{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:37:32Z","timestamp":1756993052472},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1990,10,1]],"date-time":"1990-10-01T00:00:00Z","timestamp":654739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1990,10]]},"DOI":"10.1007\/bf02657060","type":"journal-article","created":{"date-parts":[[2007,7,16]],"date-time":"2007-07-16T21:58:43Z","timestamp":1184623123000},"page":"63-69","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition"],"prefix":"10.1007","volume":"39","author":[{"given":"G.","family":"Barnett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Carb\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02657060_CR1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/j.1552-4604.1988.tb05741.x","volume":"28","author":"G Arcieri","year":"1988","unstructured":"Arcieri G, Griffith E, Gruenwaldt G, Heyd A, O\u2019Brien B, Screen P, Becker N, August R (1988) A survey of clinical experience with ciprofioxacin, a new quinolone antimicrobial. J Clin Pharmacol 28:179\u2013189","journal-title":"J Clin Pharmacol"},{"key":"BF02657060_CR2","first-page":"1673","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeu- tics","author":"LZ Benet","year":"1985","unstructured":"Benet LZ, Sheiner LB (1985) Appendix II, Pharmacokinetic con- stants. In: Gilman AG, Goodman LS, Rall TW, Murad M (eds) Goodman and Gilman\u2019s the pharmacological basis of therapeu- tics, 7th ed. MacMillan, New York, p 1673","edition":"7th ed."},{"key":"BF02657060_CR3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00609246","volume":"35","author":"J Beckman","year":"1988","unstructured":"Beckman J, ElsaberW, Gundert-Remy U, Hertramp fR (1988) Enoxacin, a potent inhibitor of theophylline metabolism. Eur J Clin Pharmaco1 35:161\u2013165","journal-title":"Eur J Clin Pharmaco1"},{"key":"BF02657060_CR4","unstructured":"Berman M, Weiss MF (1975) SAAM Manual, Berman M, Beltz W, Greif P, ChabayR, Boston R (eds) ConSam User\u2019s Guide. c\/o L. A. Zech, Rm 4B56, Bldg 10, Laboratory of Mathematical Biol- ogy, NCI, National Institutes of Health, Bethesda MD 2089"},{"key":"BF02657060_CR5","first-page":"98","volume":"32","author":"J Blanchard","year":"1982","unstructured":"Blanchard J, Sawers SJA (1982) The absolute bioavailability of caf- feine in man. Eur J Clin Pharmaco1 32:98\u2013106","journal-title":"Eur J Clin Pharmaco1"},{"key":"BF02657060_CR6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/00003495-198835040-00003","volume":"35","author":"DB Campoli-Richards","year":"1988","unstructured":"Campoli-Richards DB, Monk JR Price A (1988) Ciprofloxacin: a re- view of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 35:373\u2013347","journal-title":"Drugs"},{"key":"BF02657060_CR7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.1989.23","volume":"45","author":"M Carb\u00f3","year":"1989","unstructured":"Carb\u00f3 M, Segura J, de la Torre R, Cami J, Badenas J (1989) Effect of quinolones on caffeine disposition. Clin Pharmacol Therap 45: 234\u2013240","journal-title":"Clin Pharmacol Therap"},{"key":"BF02657060_CR8","first-page":"226","volume":"i","author":"BI Davies","year":"1987","unstructured":"Davies BI, Maesens FPV, Baur C (1987) Ciprofloxacin in the treat- ment of acute exacerbations of chronic bronchitis. Eur J Clin Microbiol i: 226\u2013231","journal-title":"Eur J Clin Microbiol"},{"key":"BF02657060_CR9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-198815030-00004","volume":"15","author":"D Edward","year":"1988","unstructured":"Edward D, Bowles S, Svensson C, Rybak M (1988) Inhibition of drug metabolism by quinolone antibiotics. Clin Pharmacokin 15: 194\u2013204","journal-title":"Clin Pharmacokin"},{"key":"BF02657060_CR10","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D (1982) Pharmacokinetics, 2. ed., Marcel Dek- ker, New York","edition":"2. ed."},{"key":"BF02657060_CR11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/BF00637602","volume":"35","author":"S Harder","year":"1988","unstructured":"Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM (1988) 4-Quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmaco1 35:651\u2013656","journal-title":"Eur J Clin Pharmaco1"},{"key":"BF02657060_CR12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/clpt.1988.109","volume":"44","author":"G Ho","year":"1988","unstructured":"Ho G, Tierney M, Dales R (1988) Evaluation of the effect of nor- floxacin on the pharmacokinetics theophylline. Clin Pharmacol Ther 44:35\u201338","journal-title":"Clin Pharmacol Ther"},{"key":"BF02657060_CR13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2165\/00003495-198530060-00003","volume":"30","author":"B Holmes","year":"1985","unstructured":"Holmes B, Brogen RN, Richards DM (1985) Norfloxacin: A review of its antibacterial activity, pharmacokinetic properties and its therapeutic use. Drugs 30:482\u2013513","journal-title":"Drugs"},{"key":"BF02657060_CR14","first-page":"252","volume-title":"Proceedings of first Symposium of Cipro- floxacin","author":"F Khan","year":"1985","unstructured":"Khan F, Raoof S (1985) Ciprofloxacin in the treatment of respir- atory tract infections. Proceedings of first Symposium of Cipro- floxacin. Leverkussen. Excerpta Medica, Amsterdam, pp 252\u2013256"},{"key":"BF02657060_CR15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/j.1552-4604.1988.tb05740.x","volume":"28","author":"DE Nix","year":"1988","unstructured":"Nix DE, Schentag JJ (1988) The quinolones: An overview and com- parative appraisal of their pharmacokinetics and pharmacody- namics. J Clin Pharmaco1 28:169\u2013178","journal-title":"J Clin Pharmaco1"},{"key":"BF02657060_CR16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/jac\/19.2.263","volume":"19","author":"DE Nix","year":"1987","unstructured":"Nix DE, DeVito JM, Whitbread MA, Schentag JJ (1987) Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theo- phylline and indocyanine green. J Antimicrob Chemother 19: 263\u2013269","journal-title":"J Antimicrob Chemother"},{"key":"BF02657060_CR17","first-page":"589","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"TW Rall","year":"1985","unstructured":"Rall TW (1985) The methylxanthines. In: Gilman AG, Good- man LS, Rall TW, Murad M (eds) Goodman and Gilman\u2019s the pharmacological basis of therapeutics, 7th ed. MacMillan, New York, p 589\u2013503","edition":"7th ed."},{"key":"BF02657060_CR18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0002-9343(87)90623-1","volume":"82","author":"C Ramirez-Ronda","year":"1987","unstructured":"Ramirez-Ronda C, Colon M, Saavedra S, Sabbaj J, Corrado ML (1987) Treatment of urinary tract infections with norfloxacin. Am J Med 82: 75\u201378","journal-title":"Am J Med"},{"key":"BF02657060_CR19","first-page":"88","volume":"32","author":"S Raoof","year":"1985","unstructured":"Raoof S, Wollschlager C, Knan F (1985) Serum theophylline levels are increased by ciprofloxacin, a new quinolone antibiotic. Chest 32(S):88","journal-title":"Chest"},{"key":"BF02657060_CR20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/clpt.1988.197","volume":"44","author":"MC Rogge","year":"1988","unstructured":"Rogge MC, Solomon WR, Sedman AJ, Welling PG, Toothaker RD, Wagner JG (1988) The theophylline enoxacin interaction: I. Effect of enoxacin dose size on theophylline disposition. Clin Pharmacol Ther 44:579\u2013587","journal-title":"Clin Pharmacol Ther"},{"key":"BF02657060_CR21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF01059791","volume":"1","author":"M Rowland","year":"1973","unstructured":"Rowland M, Martin S (1973) Kinetics of drug-drug interactions. J Pharmacokin Biopharm 1: 553\u2013567","journal-title":"J Pharmacokin Biopharm"},{"key":"BF02657060_CR22","first-page":"14","volume":"1","author":"Jose Valverde L San","year":"1986","unstructured":"San Jose Valverde L, Dominguez AR, Garcia A, Rodriguez M, Blanco JG (1986) Efectos del acido pipemidico sobre el acla- ramiento de teofilinas. Rev Esp Allergol Immunol Clin 1:14\u201316","journal-title":"Rev Esp Allergol Immunol Clin"},{"key":"BF02657060_CR23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/BF00543982","volume":"32","author":"M Sano","year":"1987","unstructured":"Sano M, Yamamoto I, Ueda J, Yokishawa H, Yamashima H, Goto M (1987) Comparative pharmacokinetics of theophylline following two fluoroquinolones coadministration. Eur J Clin Pharmaco1 32:431\u2013432","journal-title":"Eur J Clin Pharmaco1"},{"key":"BF02657060_CR24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00609246","volume":"35","author":"M Sano","year":"1988","unstructured":"Sano M, Kawakatsu K, Ohkita C, Yamamoto I, Takeyama M, Yamashina H, Goto M (1988) Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans. Eur J Clin Pharmaco1 35:161\u2013165","journal-title":"Eur J Clin Pharmaco1"},{"key":"BF02657060_CR25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/BF01061759","volume":"15","author":"PN Shaw","year":"1987","unstructured":"Shaw PN, Houston JB (1987) Kinetics of drug metabolism inhibi- tion; Use of metabolite concentration-time profiles. J Pharmaco- kinet Biopharm 15:497\u2013510","journal-title":"J Pharmaco- kinet Biopharm"},{"key":"BF02657060_CR26","doi-asserted-by":"crossref","first-page":"441446","DOI":"10.1128\/AAC.7.4.441","volume":"7","author":"M Shimizu","year":"1975","unstructured":"Shimizu M, Nakamura S, TakaseY, Kurobe N (1975) Pipemidic acid: absorption, distribution and excretion. Antimicrob Agents Chemother 7:441446","journal-title":"Antimicrob Agents Chemother"},{"key":"BF02657060_CR27","first-page":"!61","volume":"II","author":"KJ Simpson","year":"1985","unstructured":"Simpson KJ, Brodie MJ (1985) Convulsions related to enoxacin. Lancet II: !61","journal-title":"Lancet"},{"key":"BF02657060_CR28","first-page":"193","volume":"9","author":"AH Staib","year":"1987","unstructured":"Staib AH, Harder S, Mieke S, Beer C, Stille W, Shah P (1987) Gy-rase-inhibitors impair caffeine elimination in man. Methods Find Exp Clin Pharmacol 9:193\u2013198","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"BF02657060_CR29","first-page":"435436","volume":"33","author":"AH Thomson","year":"1987","unstructured":"Thomson AH, Thomson GD, Hepburn M, Withing B (1987) A clinically significant interaction between ciprofloxacin and theo- phylline. Eur J Clin Pharmaco1 33:435436","journal-title":"Eur J Clin Pharmaco1"},{"key":"BF02657060_CR30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1128\/AAC.31.4.535","volume":"7","author":"AH Willigen Van der","year":"1987","unstructured":"Van der Willigen AH, Van der Hoek JCS, Wagenvoort JHT (1987) Comparative double-blind study of 200 and 400 mg enoxacin given orally in the treatment of acute uncomplicate urethral gonorrhea in males. Antimicrob Agents Chemother 7: 535\u2013538","journal-title":"Antimicrob Agents Chemother"},{"key":"BF02657060_CR31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0140-6736(84)90283-6","volume":"II","author":"WJA Wijnands","year":"1984","unstructured":"Wijnands WJA, van Herwaarden CLA, Vree TB (1984) Enoxacin raises plasma theophylline concentrations. Lancet II: 108","journal-title":"Lancet"},{"key":"BF02657060_CR32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2125.1986.tb02985.x","volume":"22","author":"WJA Wijnands","year":"1986","unstructured":"Wijnands WJA, Vree TB, Van Herwaarden CLA (1986) The in- fluence of quinolone derivatives on theophylline clearance. Br J Clin Pharmaco1 22: 67\u2013683","journal-title":"Br J Clin Pharmaco1"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02657060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02657060\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02657060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T15:29:53Z","timestamp":1629386993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02657060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,10]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1990,10]]}},"alternative-id":["BF02657060"],"URL":"https:\/\/doi.org\/10.1007\/bf02657060","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,10]]}}}